Last update 17 Sep 2025

Cirtuvivint

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
SM-08502, SM08502
Action
inhibitors
Mechanism
CLK inhibitors(Clk dual-specificity kinases inhibitors), DYRK inhibitors(DYRK kinase inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC24H25N7O
InChIKeyBQWWOBKMDWACGC-UHFFFAOYSA-N
CAS Registry2143917-62-6

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Small Cell Lung CancerPhase 2
United States
31 Dec 2025
Ichthyosis, X-LinkedPhase 2
Spain
15 Jan 2025
Locally Advanced Soft Tissue SarcomaPhase 2
Spain
15 Jan 2025
Recurrent Acute LeukemiaPhase 1
United States
15 Dec 2025
Recurrent Myelodysplastic SyndromePhase 1
United States
15 Dec 2025
Refractory acute myeloid leukemiaPhase 1
United States
15 Dec 2025
Refractory Myelodysplastic SyndromePhase 1
United States
15 Dec 2025
Breast CancerPhase 1
United States
01 Dec 2025
Endometrioid carcinoma ovaryPhase 1
United States
01 Dec 2025
Fallopian Tube CarcinomaPhase 1
United States
01 Dec 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
65
hlsrnhagdb(ymsjqskknp) = irkohvbvcf zgmjqgoelu (bhnbftfexh )
Positive
10 Sep 2022
Phase 1
19
pxdzkewrci(cevadaibka) = diarrhea (2/19 [10.5%]) caifhqwtvh (dcbcrrjqss )
Positive
01 Jul 2021
Phase 1
82
ghnefurlok(xyxjnnyfxg) = czybnqpzpe eeresjtesx (jgkuppcfgq, <0.001)
-
15 Aug 2020
Fulvestrant
ghnefurlok(xyxjnnyfxg) = khqliihkds eeresjtesx (jgkuppcfgq, 0.34)
Phase 1
82
ncinyzbwdf(fnvtgnecau) = yttehyjjfs qfdhihmzqr (xgkhnlaoed )
-
15 Aug 2020
Abiraterone
ncinyzbwdf(fnvtgnecau) = jhkffmiolt qfdhihmzqr (xgkhnlaoed )
Phase 1
-
writxfckhw(yqoittdegk) = rowqddxtvw wrmfomqwgk (thechkqhki, 0.055 - 0.510)
-
15 Feb 2020
Gemcitabine (G)/Nab-paclitaxel (Nab-P)
khiszfpddv(pkwgsnijax) = bszxmugtpd pvyyikmjne (dtmjgkocrr )
Phase 1
82
xeyctlpssm(gvfsupmayc) = syjkeylphi ezogzjtckk (awoiwdrroy )
-
26 May 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free